Research programme: Alzheimer's disease immunotherapy - Acumen/Merck

Drug Profile

Research programme: Alzheimer's disease immunotherapy - Acumen/Merck

Alternative Names: anti-ADDL antibodies; HuC 091

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northwestern University
  • Developer Acumen Pharmaceuticals
  • Class Antibodies; Vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Injection)
  • 21 Dec 2011 Merck & Co terminates its worldwide license for ADDL monoclonal antibody and vaccine technology
  • 29 Mar 2010 Active development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top